Modulation of Renin‐Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objectives: To assess the effect of modulation of the renin‐angiotensin system ( RAS ) on conversion to Alzheimer's disease ( AD ) and cognitive decline in people with mild cognitive impairment ( MCI ) and the effect of the permeability of the blood–brain barrier ( BBB ) and race on the potential relationship between the RAS and AD . Design: Analysis of data from AD centers funded by the National Alzheimer's Coordinating Center, National Institute on Aging. Setting: Alzheimer's Disease Centers. Participants: Individuals receiving antihypertensive medications who had MCI at baseline and had cognitive assessments on at least two follow‐up visits (N = 784; mean age 75 l 48/% male). Measurements: Conversion to AD and cognitive and functional decline. Results: Four hundred eighty‐eight participants were receiving RAS ‐acting antihypertensive medications. RAS ‐acting medication users were less likely to convert to AD (33% vs 40%; P = .04) and had slower decline on the Clinical Dementia Rating Sum of Boxes ( CDR ‐ SOB , P = .005) and Digit Span Forward ( P = .02) than nonusers. BBB ‐crossing RAS ‐acting medications were associated with slower cognitive decline on the CDR ‐ SOB , ( P = .009), the Mini‐Mental State Examination ( MMSE ), ( P = .001), and the Boston Naming test ( P = .002). RAS ‐acting medications were associated with cognitive benefits more in African Americans than in Caucasians ( MMSE , P = .05; category fluency, P = .04; Digit Span Backward, P = .03). Conclusion: RAS ‐acting medication users were less likely to convert to AD . BBB permeability may produce additional cognitive benefit, and African Americans may benefit more from RAS modulation than Caucasians. Results highlight the need for trials investigating RAS modulation during prodromal disease stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study
Kivipelto, M., Helkala, E.-L., Hänninen, T., Laakso, M. P., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · Neurology · doi:10.1212/wnl.56.12.1683 · Cited by 717 · cited 1×
“Midlife high blood pressure (BP) is associated with cognitive and functional decline and has been found to be a risk factor for Alzheimer’s disease (AD).(1) Similarly, research shows that reductions in BP through lifestyle intervention or medication may be associated with protection against cognitive decline and AD.”
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547 · cited 9×
“Most cohort studies and metaanalyses include cognitively normal individuals or those with established AD.”
InfluentialOnder, G., Penninx, B. W., Balkrishnan, R., Fried, L. P., Chaves, P. H., Williamson, J., Carter, C., Bari, M. D., Guralnik, J. M., & Pahor, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08024-8 · Cited by 339 · cited 1×
“In studies assessing functional ability of individuals with AD, RAS-acting medications have been associated with greater exercise tolerance and less risk of falls.(28) A recent secondary analysis from a randomized trial showed that treatment with centrally acting RAS-acting medications reduced functional decline in in…”
Effect of literacy on neuropsychological test performance in nondemented, education-matched elders
MANLY, J. J., JACOBS, D. M., SANO, M., BELL, K., MERCHANT, C. A., SMALL, S. A., & STERN, Y. (1999) · Journal of the International Neuropsychological Society · doi:10.1017/s135561779953302x · Cited by 250 · cited 1×
“Some research shows that African Americans are at higher risk for AD and hypertension than Caucasians, although research regarding reading level and education quality may explain some of the AD-related discrepancies.(31) Although not observed in this study, differences typically exist in the types of BP medications pr…”
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59bf3 · Cited by 232 · cited 1×
“with AD undergoing treatment of atherosclerosis and dyslipidemia than in untreated individuals.(23) In studies investigating conversion from MCI to AD, one study reported that treatment with any antihypertensive therapy was associated with slower disease conversion but only in participants with circulatory dysregulati…”
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Within the Brain: The Renin Angiotensin System
Jackson, L., Eldahshan, W., Fagan, S., & Ergul, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030876 · Cited by 336
“This difference existed despite a higher mean blood pressure in the RAS medications group [128].”
BackgroundBartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202
Kehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Impact of COVID-19 on Alzheimer’s Disease Risk: Viewpoint for Research Action
Abate, G., Memo, M., & Uberti, D. (2020) · Healthcare · doi:10.3390/healthcare8030286 · Cited by 56
Yasar, S., Schuchman, M., Peters, J., Anstey, K. J., Carlson, M. C., & Peters, R. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0674-1 · Cited by 29
Metadata
- Authors
- Wharton, W., Goldstein, F. C., Zhao, L., Steenland, K., Levey, A. I., & Hajjar, I.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2015-09
- Volume
- 63
- Issue
- 9
- Pages
- 1749-1756
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1898219529
- Cited by
- 89
- References
- 6
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.